Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Tofacitinib may help treat severe hair loss, but more research is needed.

Baricitinib is effective and safe for treating severe alopecia areata.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

This therapy effectively treats resistant alopecia areata with minimal side effects.

COVID-19 doesn't make alopecia areata worse.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

Ritlecitinib is effective and safe for long-term treatment of alopecia areata.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.

Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.

Upadacitinib improved multiple immune-related conditions in one patient.